Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.35 Million EUR | -27.05% |
| 2022 | 5.97 Million EUR | -2.78% |
| 2021 | 6.14 Million EUR | 7.23% |
| 2020 | 5.72 Million EUR | 94.91% |
| 2019 | 2.93 Million EUR | -9.38% |
| 2018 | 3.24 Million EUR | 45.47% |
| 2017 | 2.22 Million EUR | 15.28% |
| 2016 | 1.93 Million EUR | -6.31% |
| 2015 | 2.06 Million EUR | -9.87% |
| 2014 | 2.29 Million EUR | 60.51% |
| 2013 | 1.42 Million EUR | 776.5% |
| 2012 | 162.8 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 4.35 Million EUR | -27.05% |
| 2023 Q4 | 4.35 Million EUR | 0.0% |
| 2023 Q2 | 4.52 Million EUR | 0.0% |
| 2022 FY | 5.97 Million EUR | -2.78% |
| 2022 Q2 | 6.23 Million EUR | 0.0% |
| 2022 Q4 | 5.97 Million EUR | 0.0% |
| 2021 Q4 | 6.14 Million EUR | 0.0% |
| 2021 FY | 6.14 Million EUR | 7.23% |
| 2021 Q2 | 5.41 Million EUR | 0.0% |
| 2020 Q2 | 3.89 Million EUR | 0.0% |
| 2020 FY | 5.72 Million EUR | 94.91% |
| 2020 Q4 | 4.32 Million EUR | 0.0% |
| 2019 Q2 | 3.66 Million EUR | 0.0% |
| 2019 FY | 2.93 Million EUR | -9.38% |
| 2019 Q4 | 2.93 Million EUR | 0.0% |
| 2018 Q2 | 3.65 Million EUR | 0.0% |
| 2018 FY | 3.24 Million EUR | 45.47% |
| 2018 Q4 | 3.24 Million EUR | 0.0% |
| 2017 Q2 | 2.23 Million EUR | 0.0% |
| 2017 FY | 2.22 Million EUR | 15.28% |
| 2017 Q4 | 2.24 Million EUR | 0.0% |
| 2016 Q2 | 2.54 Million EUR | 0.0% |
| 2016 FY | 1.93 Million EUR | -6.31% |
| 2016 Q4 | 1.93 Million EUR | 0.0% |
| 2015 FY | 2.06 Million EUR | -9.87% |
| 2015 Q4 | 2.06 Million EUR | 0.0% |
| 2015 Q2 | 1.89 Million EUR | 0.0% |
| 2014 Q4 | 2.29 Million EUR | 0.0% |
| 2014 Q2 | 1.36 Million EUR | 0.0% |
| 2014 FY | 2.29 Million EUR | 60.51% |
| 2013 FY | 1.42 Million EUR | 776.5% |
| 2013 Q4 | 1.42 Million EUR | 0.0% |
| 2012 FY | 162.8 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -28.511% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 92.145% |
| Adocia SA | 13.08 Million EUR | 66.714% |
| Aelis Farma SA | 4.03 Million EUR | -7.888% |
| Biophytis S.A. | 8.27 Million EUR | 47.322% |
| Advicenne S.A. | 17.42 Million EUR | 74.999% |
| genOway Société anonyme | 7.23 Million EUR | 39.772% |
| IntegraGen SA | 1.12 Million EUR | -287.336% |
| Medesis Pharma S.A. | 1.2 Million EUR | -263.042% |
| Neovacs S.A. | 650 Thousand EUR | -570.232% |
| NFL Biosciences SA | 62.17 Thousand EUR | -6906.963% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -60.352% |
| Sensorion SA | 2.86 Million EUR | -51.859% |
| Theranexus Société Anonyme | 3.64 Million EUR | -19.585% |
| TME Pharma N.V. | 1.16 Million EUR | -273.629% |
| Valbiotis SA | 6.87 Million EUR | 36.66% |
| TheraVet SA | 1.15 Million EUR | -275.604% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 51.584% |
| argenx SE | 18.1 Million EUR | 75.938% |
| BioSenic S.A. | 28.16 Million EUR | 84.53% |
| Celyad Oncology SA | 902 Thousand EUR | -382.983% |
| DBV Technologies S.A. | 13.01 Million USD | 66.536% |
| Galapagos NV | 9.59 Million EUR | 54.601% |
| Genfit S.A. | 70.17 Million EUR | 93.792% |
| GeNeuro SA | 7.73 Million EUR | 43.698% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 17.709% |
| Innate Pharma S.A. | 39.89 Million EUR | 89.08% |
| Inventiva S.A. | 37.4 Million EUR | 88.354% |
| MaaT Pharma SA | 14.07 Million EUR | 69.048% |
| MedinCell S.A. | 58.96 Million EUR | 92.611% |
| Nanobiotix S.A. | 50.56 Million EUR | 91.384% |
| Onward Medical N.V. | 16.87 Million EUR | 74.182% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 68.171% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 90.488% |
| Oxurion NV | 12.33 Million EUR | 64.679% |
| Pharming Group N.V. | 155.29 Million EUR | 97.195% |
| Poxel S.A. | 46.9 Million EUR | 90.711% |
| GenSight Biologics S.A. | 18.42 Million EUR | 76.359% |
| Transgene SA | 1.25 Million EUR | -246.58% |
| Financière de Tubize SA | 79.2 Million EUR | 94.499% |
| UCB SA | 3.03 Billion EUR | 99.857% |
| Valneva SE | 208.81 Million EUR | 97.914% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -11364.497% |